CareDx to Report Fourth Quarter and Full Year 2022 Financial Results

February 21, 2023 |

1 min read

CareDx, Inc. announced it will report financial results for the fourth quarter and full year 2022 after market close on Monday, February 27, 2023.

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2022 after market close on Monday, February 27, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. Please reference Conference ID: 13736063. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005708/en/

Contacts

CareDx, Inc.
Investor Relations
Greg Chodaczek
investor@caredx.com

Source: CareDx, Inc.

View this news release online at:
http://www.businesswire.com/news/home/20230221005708/en

Earnings